Vera Therapeutics (VERA) Total Current Liabilities (2020 - 2026)

Vera Therapeutics has reported Total Current Liabilities for 7 years, with the latest figure at $45.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 106.22% year-over-year to $45.1 million; the trailing twelve-month figure through Mar 2026 stood at $45.1 million (up 106.22% YoY), and the FY2025 full-year result was $53.5 million, up 110.69% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $45.1 million, down from $53.5 million in the prior quarter.
• The five-year high for Total Current Liabilities was $53.5 million in Q4 2025, with the low at $14.5 million in Q1 2024.
• Historically, Total Current Liabilities has averaged $26.9 million across 5 years, with a median of $24.6 million in 2023.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 432.08% — and 2024, when it tumbled 38.19%.
• Vera Therapeutics' Total Current Liabilities stood at $25.6 million in 2022, then declined by 12.88% to $22.3 million in 2023, then gained by 13.76% to $25.4 million in 2024, then surged by 110.69% to $53.5 million in 2025, then fell by 15.54% to $45.1 million in 2026.
• The last three Total Current Liabilities figures came in at $45.1 million (Q1 2026), $53.5 million (Q4 2025), and $41.9 million (Q3 2025), per Business Quant data.